BAL Fluid Biomarkers in Sarcoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Ability to understand and willingness to sign a written informed consent document
Diagnosed with soft tissue sarcoma
Undergoing resection of lung lesion as part of standard care
Disqualifiers
None
Trial design
Treatments tested in this trial
- Bronchoscopy & Metastasectomy
Treatment groups
70 Participants
are divided into 1 treatment groupLocations
1Radiation Medicine Program, Princess Margaret Cancer Centre, University Health NetworkM5G 2M9, TorontoOntario, Canada
Sponsors and collaborators
University Health Network, Toronto
Lead sponsor
Source ClinicalTrials.gov